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Abstract. It is currently unknown whether patients with dementia with Lewy bodies (DLB) with relatives with dementia or
Parkinson’s disease (familial DLB patients) have a different phenotype than sporadic DLB patients. In this study, we aimed to
examine disease onset, rate of cognitive decline, survival and Alzheimer’s disease (AD) biomarkers in patients with dementia
with Lewy bodies (DLB) with a family history of dementia or Parkinson’s disease (familial DLB, n = 154) and sporadic
DLB patients (n = 137), using linear mixed model analysis and Cox regression analysis, among others. Familial patients had
a shorter survival (8.0 years) and more often elevated cerebrospinal fluid AD biomarkers (47%) than sporadic patients (9.0
years; p≤ 0.001; 30%, p = 0.037). Our findings suggest that genetic factors are important in DLB and that the identification
of new genetic factors will probably improve the prediction of prognosis.
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INTRODUCTION
Dementia with Lewy bodies (DLB) is one of
the most common forms of degenerative demen-
tia in the older population [1]. DLB is diagnosed
when dementia is accompanied by at least two of
the following four core clinical features: parkinson-
ism, visual hallucinations, fluctuating cognition, and
rapid eye movement (REM) sleep behavior disor-
ders (RBD). DLB can also be diagnosed based on
dementia with one core clinical feature, in the pres-
ence of reduced dopamine transporter uptake in the
basal ganglia, abnormal 123iodine-MIBG myocar-
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dial scintigraphy, or polysomnographic confirmation
of RBD [2]. Symptoms of DLB are not specific
to the disease, but overlap with clinical features
of Parkinson’s disease (PD), PD dementia (PDD),
and Alzheimer’s disease (AD) [1]. The distinction
between DLB and PDD is most challenging, and
based on differences in time between onset of demen-
tia and parkinsonism. In PDD, dementia occurs in the
context of well-established PD as opposed to DLB,
in which dementia occurs before or concurrently
with parkinsonism [2]. In addition, pathological
and genetic features are also shared between DLB,
PD(D), and AD [1, 3, 4]. For example, Lewy bodies
containing the -synuclein protein are the pathologi-
cal hallmark of DLB, but are also observed in PD(D)
[1], and genetic factors, such as the APOE 4 allele
and GBA variants, are risk factors for DLB as well
as for AD and PD(D), respectively [3, 4]. However,
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genetic risk factors for AD and PD seem to explain
a part of the total phenotypic variance in DLB only
[5–7].
Recent studies have indicated that genetic factors
play an important role in DLB. The heritable com-
ponent of DLB has even been estimated at 60% [7].
Families with multiple DLB patients have rarely been
described [3, 8]. However, it has been reported that
siblings of DLB patients are at higher risk of devel-
oping DLB compared to siblings of AD patients [9].
Furthermore, DLB patients more often have a family
history of PD or dementia than controls [10, 11]. This
finding supports the notion that DLB, PD and demen-
tia share, at least partially, the same genetic factors.
This in turn might lead to shared molecular pathways
and possibly similar phenotypes.
The APOE 4 allele has been associated with
a shorter survival in DLB [12–14] and disease-
associated genetic variants in GBA have been
associated with an earlier age of onset and death
in DLB [15–17]. However, it is currently unknown
whether DLB patients with relatives with dementia
or PD (familial DLB) have a different phenotype than
sporadic DLB patients. The main aim of this study is
to examine the role of family history, used as a proxy
of genetic factors, in relation to disease onset, rate of
cognitive decline, survival, and AD biomarkers. The
secondary aim of this study is to explore the afore-
mentioned features in DLB patients with relatives
with dementia or PD to examine if their phenotype is
more similar to AD or PD.
MATERIALS AND METHODS
Patients and study design
This is a retrospective study in which demographic
and clinical data were collected from patients’
medical records. Information on the occurrence of
dementia and/or PD in first degree relatives was based
on medical records (41%) or a standardized assess-
ment (59%), using a questionnaire or an additional
patient/family member interview. A nation-wide reg-
istration system containing demographic data about
all Dutch citizens was consulted to obtain informa-
tion about dates of death (collected until December
2018).
A total of 291 patients with probable DLB accord-
ing to the criteria of Mckeith et al. [18] were enrolled
from three hospitals in the Netherlands (Elisabeth-
TweeSteden Hospital, Tilburg; Erasmus Medical
Center, Rotterdam; Amsterdam University Medical
Center, Amsterdam). Patients visited the outpatient
clinics of the Neurology departments between 2000
and 2018 and were diagnosed by expert neurologists.
Dopamine transporter uptake scans were performed
in 128 patients, and were used in the diagnostic pro-
cess. Familial patients were defined as patients with
at least one first degree relative with dementia or PD.
Sporadic patients were defined as patients without
first degree relatives with dementia or PD. Patients
were excluded from the study when no dementia
or PD was diagnosed in relatives together with no
information on the occurrence of the other disease in
relatives (e.g. no relatives with PD and no informa-
tion of the occurrence of dementia, or vice versa), and
when no information on family history was available
at all. The distribution of the different groups accord-
ing to family history is depicted in Supplementary
Figure 1.
The study was performed according to the ethi-
cal principles of the Declaration of Helsinki and was
approved by the local ethics committees (Elisabeth-
TweeSteden Hospital: MEC-2016-608, L0318.2016;
Erasmus Medical Center: MEC-2015-304, MEC-
2016-608; Amsterdam University Medical Center:
MEC-2016-061, MEC-2017-2116).
Outcome measures
Several clinical features and AD biomarkers (i.e.
the presence of medial temporal lobe atrophy (MTA)
[19], a CSF tau/amyloid-1-42 (A42) ratio of >0.52
[20], and ≥1 APOE 4 allele(s) [21]), were explored
with respect to family history in DLB.
Age of onset and type of first symptom were based
on anamnestic information from the patient or family
members. We categorized the type of first symptom
into cognitive decline, parkinsonism, and halluci-
nations. Cognitive decline included descriptions of
memory impairment and executive function impair-
ment. Parkinsonism was based on bradykinesia with
muscular rigidity, rest tremor, or postural instability
[22] or when parkinsonism was noted in the medical
files in absence of more specific information. Rate of
cognitive decline was based on the available Mini-
Mental State Examination (MMSE) scores [23].
Survival was defined as the time between age of onset
and death. Magnetic resonance imaging (MRI) scans
were evaluated visually and rated according to the
MTA scale [19] by radiologists for clinical purposes.
CSF was collected by lumbar puncture in polypropy-
lene tubes (Starstedt, Nu¨mbrecht, Germany). Levels
of A42, total tau, and p-tau were measured with
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commercially ELISAs (Innotest®, Fujirebio, Gent,
Belgium). APOE genotyping was performed using
the LightCycler APOE mutation detection method
(Roche Diagnostics GmbH, Mannheim, Germany)
after genomic DNA extraction.
Data analysis
Differences in sex, age of onset, type of first
symptom, and APOE genotype between familial
and sporadic DLB were explored using the χ2 test,
Fisher’s exact test, Fisher-Freeman-Halton test, inde-
pendent Student t test, or Mann-Whitney U test,
where appropriate. We analyzed the MTA score and
CSF tau/A42 ratio of >0.52 (CSF AD biomark-
ers) between the groups using linear and logistic
regression, respectively, with time between age of
onset and date of MRI or lumbar puncture as covari-
ate to correct for possible confounding by disease
stage. Linear mixed model analysis was performed
to assess changes in MMSE levels over time, while
accounting for the correlation between the repeated
measurements of each patient. The model included
time since first MMSE, family history, and an inter-
action effect between time and family history to
assess differences in the course of cognitive decline
between groups. All MMSEs which were adminis-
tered within 6 months from the previous MMSE were
removed, because of possible learning effects. In the
random effect structure, covariance type was set on
unstructured and a random intercept was included.
Differences in survival between familial and sporadic
DLB were explored using Kaplan-Meier analysis and
Cox regression analysis. We included sex, age of
onset, and study center to correct for possible con-
founding in the linear mixed model analysis and the
Cox regression analysis.
In addition, differences in phenotype between DLB
patients with a family history of either dementia or PD
were explored. Statistical analyses were performed as
described above.
Statistical significance for all tests was established
at p < 0.05 (two-tailed). The data was analyzed using
SPSS software (Version 24).
RESULTS
Differences in phenotype between patients with
familial and sporadic DLB
The 154 familial DLB patients and the 137 spo-
radic DLB patients did not differ in sex, age of onset,
type of first symptom (Table 1), or rate of cogni-
tive decline (Table 2). Significantly more familial
DLB patients had elevated CSF biomarkers for AD
(47%), compared to those with sporadic DLB (30%,
p = 0.039). This finding remained significant after
correction for time between age of onset and date
of lumbar puncture (p = 0.037, Table 1). In addition,
a borderline significant result was found concerning
the APOE 4 allele, with a higher frequency of this
allele in familial patients (65%) compared to spo-
radic patients (51%, p = 0.069). MTA score was not
different between the groups (Table 1).
Differences in survival between patients with
familial and sporadic DLB
A total of 154 patients (53.1%) were deceased
with a median survival of 7.0 years (IQR 5.0–9.0).
Uncorrected survival analysis showed that patients
with familial DLB had a significantly shorter survival
(median 8.0 years, SE 0.51) compared to patients with
sporadic DLB (median 9.0 years, SE 0.63, p≤ 0.001,
Table 2 and Fig. 1). This finding remained significant
after correction for sex, age of onset and study center
(HR 1.64, 95% CI: 1.16–2.31, p = 0.005, Table 2).
Differences in phenotype between DLB patients
with a family history of either dementia or PD
A total of 84 patients had a family history of
either dementia (n = 69) or PD (n = 15) (Supplemen-
tary Figure 1). Parkinsonism was more prevalent as
first symptom in DLB patients with a family history
of PD (33%) compared to the patients with a family
history of dementia (6%, p = 0.008). These groups
did not differ in sex, age of onset (Supplementary
Table 1), or rate of cognitive decline (Supplementary
Table 2).
In addition, there were no significant differences
in the presence of the APOE 4 allele, CSF AD
biomarkers, and MTA score between the groups (Sup-
plementary Table 1).
Differences in survival between DLB patients
with a family history of either dementia or PD
A total of and 43 patients (51.2%) were deceased
with a median survival of 8.0 years (IQR 5.0–10.0).
There were no differences in survival between DLB
patients with relatives with dementia as compared to
DLB patients with relatives with PD (Supplementary
Table 2).
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Table 1
Demographic features, clinical features and biomarkers in the total study group, and group differences
Total Familial DLB Sporadic DLB p
(n = 291) (n = 154) (n = 137)
Study center 0.011∗
Elisabeth-TweeSteden Hospital 35 (12%) 24 (16%) 11 (8%)
Erasmus Medical Center 54 (19%) 20 (13%) 34 (25%)
Amsterdam University Medical Center 202 (69%) 110 (71%) 92 (67%)
Sex, male 232 (80%) 122 (79%) 110 (80%) 0.82
Age of onset, y 66.0 (7.6) 66.6 (8.4) 65.3 (6.7) 0.14
First symptom
Cognitive decline 245 (84%) 133 (86%) 112 (82%) 0.28
Parkinsonism 29 (10%) 14 (9%) 15 (11%) 0.60
Hallucinations 17 (6%) 7 (5%) 10 (7%) 0.32
MTA score (average of right and left) (n = 199 [98;101]) 1 (0.5–1.5) 1 (0.5–1.5) 1 (0–1.1) 0.10a
CSF tau/A42 ratio >0.52 (n = 169 [83;86]) 65 (38%) 40 (47%) 25 (30%) 0.037a,∗
APOE 4 carrier (n = 160 [76;84]) 94 (59%) 55 (65%) 39 (51%) 0.069
Values are presented as mean (SD), median (IQR) or n (%). DLB, dementia with Lewy bodies; PD, Parkinson’s disease;
CSF, cerebrospinal fluid; MTA, medial temporal lobe atrophy, A42, amyloid-1-42, acorrected for time between age of
onset and date of MRI or date of lumbar puncture, ∗p < 0.05.
Table 2
Statistical models regarding rate of cognitive decline and survival in the total study group
Rate of cognitive decline  SE 95% CI p
Uncorrected Baseline –0.47 0.59 –1.63–0.70 0.43
(Linear mixed model analysis) Change over time –0.0090 0.017 –0.041–0.024 0.59
With correction for sex, age of onset, and study center Baseline –0.34 0.59 –1.50–0.81 0.56
(Linear mixed model analysis) Change over time –0.0091 0.016 –0.042–0.023 0.59
Survival Mediana SE 95% CI p
Uncorrected Sporadic DLB 9.0 0.63 7.77–10.23 <0.001∗
(Kaplan-Meier analysis) Familial DLB 8.0 0.51 7.00–9.00
B SE HR 95% CI p Z-score
With correction for sex, age of onset, and study center 0.50 0.18 1.64 1.16–2.31 0.005∗ 5.71
(Cox regression analysis)
aTime between age of onset and death, ∗p < 0.05.
DISCUSSION
The main finding of this study is that patients with
familial DLB have a shorter survival than patients
with sporadic DLB. We also found a higher per-
centage of familial DLB patients with elevated AD
biomarkers in their CSF compared to sporadic DLB
patients. Several longitudinal studies in DLB showed
that concomitant AD pathology is associated with
a higher mortality [24–26]. The shorter survival in
familial DLB compared to sporadic DLB may be
due to concomitant AD pathology in familial DLB,
which is reflected in a higher CSF tau/A42 ratio
in familial patients compared to sporadic patients.
Genetic factors, such as the APOE 4 allele, con-
tribute to the presence of concomitant AD pathology
[25, 27]. Interestingly, although only borderline sta-
tistically significant, a higher frequency of the APOE
4 allele in familial patients compared to sporadic
patients was seen. This suggests that genetic factors
are associated with survival, possibly by influencing
neuropathology.
Previous studies have shown several possible risk
factors for a shorter survival in DLB, such as the
presence of a fluctuating cognition, hallucinations at
onset and a low MMSE score [14, 26]. Other vari-
ables have also been reported to be associated with
survival, but are contradictory between different stud-
ies (e.g. female and male sex, early and late age of
onset) [14, 26]. There were no significant differences
in these clinical characteristics between familial and
sporadic DLB patients in our study (data not shown
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Fig. 1. Survival distribution (Kaplan-Meier curve) of DLB patients
with a negative family history as compared to DLB patients with
a positive family history.
for a fluctuating cognition and MMSE score). This
might indicate that family history has an effect on
survival independent of these clinical characteristics.
In addition, we found parkinsonism to be a more
frequent presenting symptom in patients with a pos-
itive family history of PD than in patients with
a positive family history of dementia. This might
be based on more ‘pure’ Lewy body pathology in
patients with relatives with PD, and mixed pathol-
ogy (Lewy body pathology and AD pathology) in
patients with relatives with dementia. However, this
finding could also be based on recall bias due to famil-
iarity with PD symptoms. Other AD or PD features
were equally distributed between patients with a pos-
itive family history of dementia or PD, respectively.
These results should be interpreted with caution due
to the relatively small number of patients in the group
with relatives with PD and the presence of non-AD
dementias in the group with relatives with dementia.
About half of the DLB patients in this study had
at least one first degree relative with dementia or
PD. This is in line with previous studies, in which
a positive family history for dementia was observed
in 39–44% and for PD in 10–24% of patients with
DLB [10, 11]. Nonetheless, the percentages that we
found could be an overestimation as patients with
insufficient information on family history were not
taken into account. These patients might be less likely
to have relatives with relevant diseases. However, the
most important limitation of this study is its retrospec-
tive character. Furthermore, information on family
history and disease onset was based on anamnes-
tic information, and may have introduced a recall
bias. In addition, the patients in this study were pre-
dominantly male (80%), which may not be a good
representation of the general DLB population [28].
However, our main finding (familial DLB patients
have a shorter survival than sporadic DLB patients)
stayed significant after correction for sex. At last, the
DLB diagnoses in this study were not pathologically
confirmed.
Strengths of this study include its large sample size
and the enrollment of patients from university med-
ical centers as well as from a general hospital. The
latter increases the generalizability of our findings.
In conclusion, we are the first to report that DLB
patients with a positive family history of dementia or
PD have a shorter survival than DLB patients with a
negative family history of these diseases. This sug-
gests that genetic factors contribute to disease course,
possibly by influencing the amount of concomitant
AD pathology, which is supported by our data. Future
studies are necessary to identify which genetic and
other contributing factors are accountable for our
findings. This knowledge will lead to a better under-
standing of the pathophysiology of the disease and
the overlap with AD and PD(D), and will probably
improve the prediction of prognosis.
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